The serum levels of adipokines in individuals with different cardiovascular risk
https://doi.org/10.17238/PmJ1609-1175.2017.4.77-82
Abstract
Objective. Arterial hypertension (AH) is one of the most common diseases in the world and the most significant morbidity and mortality cause in working age individuals. According to the results of a multicenter epidemiological study ESSE-RF with the participation 15571 patients from ten country regions, in recent years the prevalence of hypertension in the population increased from 39.7 to 43.4%. Methods. The research included 395 individuals aged 25 to 60 years, of whom 215 patients with hypertension. All participants measured the height, weight, waist circumference, body mass index, counting the index of the smoker, determined the lipid profile and adipokine levels in serum by enzyme immunoassay. Results. In patients with hypertension compared with the control group showed a significant decrease in serum adiponectin, the content of resistin had opposite results. The lowest adiponectin concentration obtained in combinations of risk factors hypertension and smoking. Relationship between the smoking intensity and resistin concentration and adiponectin had been identified. Conclusions. The data indicated a higher factors combination contribution in the development of metabolic problems, diabetes and coronary heart disease. It is revealed that for the better definition the risk of cardiovascular accidents in individuals with traditional risk factors combination (hypertension and smoking) should to consider the adipokines definition in the serum, in particular adiponectin and resistin.
About the Authors
L. V. Rodionova
Pacific State Medical University
Russian Federation
Russian Federation
N. G. Plechova
Pacific State Medical University
Russian Federation
Russian Federation
D. Y. Bogdanov
Pacific State Medical University
Russian Federation
Russian Federation
N. V. Zaharchuk
Pacific State Medical University
Russian Federation
Russian Federation
References
1. Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенеза метаболических нарушений у женщин // Артериальная гипертензия. 2015. Т. 21, № 4. С. 356-370
2. Чазова И.Е. Артериальная гипертензия и дислипидемия: основные направления стратегии лечения больных высокого сердечно-сосудистого риска // Эффективная фармакотерапия: кардиология и ангиология. 2015. № 3. С. 42-49
3. Allison M.A., Ix J.H., Morgan C. [et al.]. Higher leptin is associated with hypertension: the Multi-Ethnic Study of Atherosclerosis // J. Hum. Hypertens. 2013. Vol. 27, No. 10. P. 617-622.
4. Efstathiou S.P., Pefanis A.V., Mountokalakis Th.D. [et al.]. Plasma Adiponectin levels and five-year survival after first-ever Ischemic // Stroke. 2005. Vol. 36. P. 1915-1919.
5. European Guidelines on cardiovascular disease prevention in clinical practice, 2016 // European Heart Journal. 2016. Vol. 37. P. 2315-2381.
6. Huocheng L., Li Z., Zheng D. [et al.]. Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness // Lipids Health Dis. 2014. Vol. 13. P. 120-125.
7. Kazumi T., Kawaguchi A., Sakai K. [et al.]. Young men with highnormal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure // Diabetes Care. 2002. Vol. 25, No. 6. P. 971-976.
8. Kubota N., Yano W., Kubota T. [et al.]. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake // Cell Metab. 2007. Vol. 6, No. 1. P. 55-68.
9. Melone M., Wilsie L., Palyha O. [et al.]. Discovery of a new role of human resistin hepotocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subutilisin/Kexin type 9 // J. Am. Coll. Cardiol. 2012. Vol. 59, No. 19. P. 1697-1705.
10. Mtiraoui N., Ezzidi I., Turki A. [et al.]. Single-nucleotide polymorphisms and haplotypes in the adiponectin gene contribute to the genetic risk for type 2 diabetes in Tunisian Arabs // Diabetes Res. Clin. Pract. 2012. Vol. 97, No. 2. P. 290-297.
11. Roth G.A., Johnson C., Abajobir A. [et al.]. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1995 to 2015 // JACC. 2017. Vol. 70, No. 1. P. 1-25.
12. Sakovskaia A., Nevzorova V., Brodskaya T., Chkalovec I. Condition aortic stiffness and content of adipokines in the serum of patients with essential hypertension in young and middle-aged // Journal of Hypertension. 2015. Vol. 33, e-Suppl. 1. P. 182.
13. Takata Y., Osawa H., Kurata M. [et al.]. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes // J. Hypertens. 2008. Vol. 51, No. 2. P. 534-539.
14. Takeishi Y., Niizeki T., Arimoto T. [et al.]. Serum resistin is associated with high risk in patients with congestive heart failure: a novel link between metabolic signals and heart failure // Circ. J. 2007. Vol. 71. P. 460-464.
15. Yoon J.-H., Kim S.-K., Choi H.-J. ^t al.]. Adiponectin provides additional information to conventional cardiovascular risk factors for assessing the risk of atherosclerosis in both genders // PLoS One. 2013. Vol. 8, No. 10. P. e75535.
Review
For citations:
Rodionova L.V., Plechova N.G., Bogdanov D.Y., Zaharchuk N.V. The serum levels of adipokines in individuals with different cardiovascular risk. Pacific Medical Journal. 2017;(4):77-82. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2017.4.77-82
Views:
284
Email this article 